HIF-1 alpha Levels in patients receiving chemoradiotherapy for locally advanced non-small cell lung carcinoma

Abstract

AIM: To examine the relationship between treatment response and hypoxia-inducible factor-1 alpha (HIF-1 alpha) levels in patients with locally advanced non-small cell lung cancer (NSCLC) who received chemoradiotherapy (CRT). METHODS: Eighty patients with NSCLC were included in the study and treated at Acibadem Mehmet Ali Aydinlar University Medical Faculty. HIF-1 alpha levels were measured before and after CRT by the enzyme-linked immunosorbent assay (ELISA) method. RESULTS: Patients' stages were as follows

stage IIIA (65\%) and stage IIIB (35\%). Squamous histology was 45\%, adenocarcinoma was 44\%, and others were 11\%. Chemotherapy and radiotherapy were given concurrently to 80 patients. Forty-five (56\%) patients received cisplatin-based chemotherapy, and 35 (44\%) received carboplatin-based chemotherapy. Serum HIF-1 alpha levels (42.90 +/- 10.55 pg/mL) after CRT were significantly lower than the pretreatment levels (63.10 +/- 10.22 pg/mL, p<0.001) in patients with locally advanced NSCLC. CONCLUSION: The results of this study revealed that serum HIF-1 alpha levels decreased after CRT Decrease of HIF-1 alpha levels after the initiation of CRT may be useful for predicting the efficacy of CRT.